A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Platinum Resistant Ovarian Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1. ECOG performance status 0 or 1. 2. Measurable disease as per RECIST, version 1.1. 3. Adequate organ function. 4. Confirmed availability of tumor tissue blocks or freshly cut tissue slides for NaPi2b testing. 5. Recurrent ovary cancer

You may not be eligible for this study if the following are true:

  • 1. Major surgery wit in 28 days of starting study treatment or systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment or recent radiation therapy with unresolved toxicity. 2. Brain metastases that are untreated, are progressive, have required any type of major treatment, or have a history of leptomeningeal metastasis. 3. Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.